Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis

Table 1 Characteristics of selected studies

Ref.	Study design	Patientinclusion criteria	ADA/IFX, n	Definition of remission	Definition of secondary loss of response	Induction of response/remission in wk	Maintenance of response/remission in wk	Adverse events	NOS
Zorzi et al[6], 2012	Retrospective	Active CD	49/44	CDAI < 150	No improvement or worsening	4/6	54	Multiple	6
Kestens et al[4], 2013	Retrospective	Naïve CD	100/100	NS	NS	NS	54	Multiple	9
Ma et al[17], 2014	Retrospective	Naïve CD	101/117	NS	Requiring dose escalation	NS	NS	NS	8
Tursi et al[15], 2014	Retrospective	CD	67/59	HBI ≤ 5	NS	6-14	NS	Multiple	8
Cosnes et al[12], 2016	Prospective	Naïve CD	264/127	CDAI < 150	Disease activity	NS	26	Multiple	8
Varma et al[8], 2016	Retrospective	Naïve CD	18/63	CDAI < 150	NS	12	48	Multiple	7
Narula et al[9], 2016	Prospective	Naïve CD	111/251	HBI < 5	Dose escalation	12	48	Multiple	8
Bau et al[14], 2017	Retrospective	Refractory CD	62/68	NS	NS	NS	168	Multiple	5
Otake et al[5], 2017	Retrospective	CD	29/39	CDAI < 150	Multiple	NS	54	NS	8
Doecke et al[16], 2017	Retrospective	CD	144/183	CDAI ≤ 150	NS	14	NS	NS	7
Benmassaoud et al[7], 2018	Retrospective	Naïve CD	77/143	HBI ≤ 4	Need for dose escalation	12	48	Multiple	8
Di Domenicantonio et al[13], 2018	Retrospective	Naïve CD	505/367	NS	NS	NS	NS	Multiple	9
Macaluso et al[10], 2019	Retrospective	Naïve and non-naïve CD	Naïve: 214/107; non-naïve: 47/47	NS	NS	12	48	Multiple	9
Kaniewska et al[11], 2019	Retrospective	CD	95/82	CDAI < 150	NS	NS	48	Multiple	7

CD: Crohn's disease; ADA: Adalimumab; IFX: Infliximab; CDAI: Crohn's disease activity index; HBI: Harvey Bradshaw Index; NOS: Newcastle-Ottawa Quality Assessment Scale; NS: Not stated.